Tofacitinib for the treatment of rheumatoid arthritis (Q34275878)

1 August 2017

Tofacitinib for the treatment of rheumatoid arthritis (English)

1 reference

1 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Cristiano A F Zerbini

series ordinal

1

1 reference

PubMed ID

22607178

1 August 2017

Andrea Barranjard Vannucci Lomonte

series ordinal

2

1 reference

PubMed ID

22607178

1 August 2017

language of work or name

1 reference

1 May 2012

1 reference

Expert Review of Clinical Immunology

1 August 2017

1 reference

1 August 2017

8

1 reference

1 August 2017

4

1 reference

1 August 2017

319-331

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 August 2017

1 reference

Evolving concepts of rheumatoid arthritis

21 January 2018

1 reference

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

21 January 2018

1 reference

Phenotypic and functional features of human Th17 cells

21 January 2018

1 reference

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort).

21 January 2018

1 reference

Regulatory T cells in rheumatoid arthritis

21 January 2018

1 reference

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

21 January 2018

1 reference

Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis

21 January 2018

1 reference

Cadherin-11 in synovial lining formation and pathology in arthritis

21 January 2018

1 reference

Cytokine networks--towards new therapies for rheumatoid arthritis

21 January 2018

1 reference

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

Janus kinases in immune cell signaling

21 January 2018

1 reference

Jaks and STATs: biological implications

21 January 2018

1 reference

New insights into the regulation of T cells by gamma(c) family cytokines

21 January 2018

1 reference

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 January 2018

1 reference

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection

21 January 2018

1 reference

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

21 January 2018

1 reference

Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6

21 January 2018

1 reference

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

21 January 2018

1 reference

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates

21 January 2018

1 reference

The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models

21 January 2018

1 reference

Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates

21 January 2018

1 reference

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists [...]

21 January 2018

1 reference

Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.

21 January 2018

1 reference

Regulation of JAK-STAT signalling in the immune system

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECI.12.19

1 reference

1 August 2017

1 reference

PubMed ID

22607178